Skip to content Skip to footer
Subscribe Now
J&J
NEWS

Johnson & Johnson Highlights Clinical Data on Caplyta (Lumateperone) for Major Depressive Disorder (MDD) at ACNP 2026

Shots: Data from the OLE 503 study of Caplyta & pooled results from P-III (Studies 501 & 502) trials assessing Caplyta vs PBO, both in combination with an antidepressant, in adults with MDD presented at ANCP’26 Pooled data showed higher remission (MADRS ≤10) with treatment at 6wks. (25.5% vs 13.6%), with complete remission (MADRS ≤5) in 10.6%…
January 19, 2026

Read more

Abbvie
NEWS

AbbVie Reports Topline P-III (EPCORE DLBCL-1) Trial Data on Epcoritamab for R/R Diffuse Large B-cell Lymphoma (DLBCL)

Shots: AbbVie has reported topline P-III (EPCORE DLBCL-1) trial results assessing epcoritamab vs chemoimmunotherapy (R-GemOx or BR) in 483 adults with r/r DLBCL, who had received ≥1L of therapy (73% had received ≥2L) & were ineligible for HDT-ASCT Trial showed improved PFS, with improvements across CRR, DoR, & time to next treatment, plus the study did not…
January 19, 2026

Read more

NEWS

AstraZeneca Secures China Rights to AbelZeta’s GPC3 Armored CAR-T Therapy for Solid Tumor

Shots: AstraZeneca to acquire AbelZeta’s 50% stake in the China development & commercialization rights to C-CAR031, securing full global rights to develop, manufacture, & commercialize C-CAR031 worldwide Under a prior agreement, AstraZeneca secured global rights to develop, manufacture, & commercialize C-CAR031 outside China, while AbelZeta remains eligible for additional development milestones & royalties tied to…
January 19, 2026

Read more

NEWS

Sobi Reports the EC Approval of Aspaveli for C3 Glomerulopathy and Primary IC-MPGN

Shots: The EC approved Aspaveli (pegcetacoplan) for pts (≥12yrs.) with C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), to be used with a RAS inhibitor unless such therapy is contraindicated or not tolerated Approval was based on P-III (VALIANT) trial assessing Aspaveli(twice weekly) vs PBO in C3G or primary IC-MPGN pts (≥12yrs., n=124) for…
January 16, 2026

Read more

NEWS

BD’s EnCor EnCompass System Secures the US FDA 510(k) Clearance for Breast Biopsy

Shots: The US FDA has granted 510(k) clearance for the EnCor EnCompass Breast Biopsy and Tissue Removal System to provide clinicians with flexibility across breast imaging modalities in the diagnosis of breast disease The EnCor EnCompass Biopsy System streamlines breast biopsy procedures by allowing clinicians to use a single integrated system across multiple imaging platforms,…
January 16, 2026

Read more

Daiichi Sankyo
NEWS

Daiichi Sankyo Initiates P-III (TROPIONLung17) Trial of Datroway in Nonsquamous NSCLC

Shots: Daiichi Sankyo has dosed the first patient in the P-III (TROPIONLung17) trial of Datroway for TROP2-NMR–positive LA/M nonsq. NSCLC without actionable genomic alterations previously treated with immunotherapy (IT) & Pt-based CT Trial will evaluate Datroway (6mg/kg) vs docetaxel in above-mentioned pts (n=~400) across Asia, EU & North America, assessing PFS & OS as dual…
January 14, 2026

Read more

NEWS

PharmaEssentia Reports the US FDA’s sBLA Acceptance of Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia

Shots: The US FDA has accepted sBLA of ropeginterferon alfa-2b-njft for the treatment of adults with essential thrombocythemia, with a PDUFA target action date of Aug 30, 2026 sBLA is supported by the statistically significant and clinically meaningful data from the P-III (SURPASS-ET) trial as well as North American P-IIb (EXCEED-ET) trial  Ropeginterferon alfa-2b-njft received…
January 14, 2026

Read more

NEWS

Zonsen PepLib Biotech Grants Novartis Global License for Radioligand Therapy Asset with $50M Upfront

Shots: Zonsen PepLib Biotech has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based radioligand therapy asset As per the deal, Novartis will obtain exclusive worldwide rights & lead the development & commercialization activities for the undisclosed asset In return, PepLib will receive $50M upfront, with additional development, regulatory, & sales milestone payments,…
January 14, 2026

Read more

Load more